AstraZeneca, Daiichi Sankyo announce Enhertu plus pertuzumab demonstrated clinically meaningful improvement as 1st-line therapy for patients with metastatic breast cancer

DESTINY-Breast09 Phase III trial of AstraZeneca and Daiichi Sankyo’s Enhertu is the first trial in more than a decade to demonstrate superior efficacy across a broad HER2-positive metastatic patient population versus current 1st-line standard of care

Vgenomics and Meril Genomics collaborate to revolutionise precision medicine

Access to NIPT, TB and Rare Disease diagnostics to benefit thousands of patients nationwide

Shin-Etsu Chemical and Hokkaido University develop lipid nanoparticle production system capable of both small-batch, high-mix production

FDA approves Medtronic’s new Simplera Sync sensor for the MiniMed 780G system

The Simplera Sync is a disposable, all-in-one sensor that requires no fingersticks with SmartGuard

Injection filter needle market to reach $1.73 billion in 2025

Rising demands and advancements in eye care drive growth

Rockwell Automation empowers NKP Pharma achieve regulatory compliance

By integrating Rockwell Automation’s FactoryTalk Optix, NKP Pharma has achieved compliance with USFDA 21 CFR Part 11

Abbott India elevates Anushree Kunhambu as Associate Director - New Product Introduction and Therapy Area Strategy

Anushree has been with Abbott since 2021 and currently serving as Head of Strategy and Portfolio

Aarti Pharmalabs achieves SBTi approval of GHG emission reduction targets

Aarti Pharmalabs becomes 6th Indian Pharma/CDMO to earn SBTi approval for all 3 Scopes since 2022 demerger

Dr. Lal PathLabs becomes South Asia's first to launch advanced test for amyloidosis

More than 40 types of Amyloid proteins are discovered till date

Biocon Biologics secures market entry date for Yesafili in US

YESAFILI, a vascular endothelial growth factor (VEGF) inhibitor, is used to treat several different types of ophthalmology conditions